GlobalData has released its new
Country report, “PharmaPoint: Multiple Sclerosis India Drug Forecast and Market
Analysis to 2022”. Multiple sclerosis (MS) is a chronic, inflammatory
neurological disorder characterized pathologically by demyelination, axonal
transection and neurodegeneration within the central nervous system. With
curative therapy still elusive, current disease management is dependent on
life-long pharmacotherapy with disease-modifying therapies (DMT). The dominance
of first-line injectable DMTs, including the interferon beta (IFNB) agents:
Bayer’s Betaseron/Betaferon (IFNB-1b), Biogen’s Avonex (IFNB-1a) and Merck’s
Rebif (IFNB-1a), and Teva’s Copaxone (glatiramer acetate), has been a salient
feature of the MS therapeutics market. However, the competitive landscape is
undergoing significant change with the emergence of oral therapies, several
pipeline products with notable efficacies, and looming generics/biosimilars
following the patent expiries of key branded products during the forecast
period. In addition, the entry of new companies such as Sanofi/Genzyme and F.
Hoffmann-La-Roche/Genentech will challenge the position of the established
players in the MS marketplace.
To
check out the table of contents, visit:
http://www.marketresearchreports.biz/analysis-details/pharmapoint-multiple-sclerosis-india-drug-forecast-and-market-analysis-to-2022
MS has a low prevalence in India,
which could be due to genetics or environmental factors. However, many
physicians surveyed for this report mostly use the Poser criteria to diagnose
patients, given the lack of current acceBibility to sensitive diagnostic tools,
such as MRI. Therefore, it is poBible that the current rate of MS in India is
groBly underestimated, meaning a large proportion of undiagnosed MS patients
are not captured and provided adequate treatment. The major drivers of growth
in this market will be the launch of oral DMTs and an increase in availability
of advanced diagnostic tools, which will likely lead to increased diagnosis and
treatment rates over the forecast period.
Note: This is upcoming report and
will be delivered within 24 hrs of the purchase (excluding weekends).
Scope
- Overview of the Multiple Sclerosis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in India including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in India from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting India Multiple Sclerosis market.
To Buy The Copy of This Report Visit: http://www.marketresearchreports.biz/analysis/166887
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Multiple Sclerosis
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed busineB decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in India
MarketResearchReports.Biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are especially designed to save time and money of our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
Email: sales@marketresearchreports.biz
Website: http://www.marketresearchreports.biz/
No comments:
Post a Comment